Drug intelligence / Profile preview

TFC-1326

Development stage
Unknown
Lead developer
Sirona Biochem
Modality
Cyclic Peptides → Modified Peptides → Peptides, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration
Topical
01

Overview

TFC-1326 is a synthetic anti-freeze glycoprotein (AFGP)-based compound developed as a topical agent for the treatment and prevention of skin aging. It acts by mimicking natural antifreeze glycoproteins, which are known to protect biological tissues from environmental stress. In preclinical and clinical studies, TFC-1326 has demonstrated the ability to restore adipogenic capacity in preadipocytes exposed to proinflammatory conditions, reduce fibroinflammatory states, stimulate dermal fibroblast proliferation and production of hyaluronic acid and procollagen type I, decrease IL-6 secretion, increase fibroblast viability, and enhance extracellular matrix remodeling. Clinically, application of a 1% TFC-1326 cream led to significant improvements in skin density (collagen/elastin), radiance, firmness/laxity reduction, hydration/texture improvement, wrinkle depth/volume reduction (notably crow’s feet), decreased inflammation (IL-8) and oxidation (H2O2), with excellent tolerability even on sensitive skin. The compound outperformed traditional retinoid-based anti-aging products in both efficacy and user tolerance[1][4][5][7][10].

Brand names
GlycoProteMim
Other names
GlycoProteMim
02

Targets

HAS1 (Hyaluronan synthase 2)IL-6 (Interleukin 6)IL8 (C-X-C Motif Chemokine Ligand 8)

Beyond the preview

Go deeper on TFC-1326.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TFC-1326.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call